OKYO Pharma Limited Activation of First Clinical Trial Site in the U.S (2686X)
25 Aprile 2023 - 8:00AM
UK Regulatory
TIDMOKYO
RNS Number : 2686X
OKYO Pharma Limited
25 April 2023
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK
LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS
(SI 2019/310) (UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT,
THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO
BE IN THE PUBLIC DOMAIN.
OKYO Pharma Announces Activation of First Clinical Trial Site in
the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment
of Dry Eye Disease
London and New York, NY, April 25, 2023 - OKYO Pharma Limited
(LSE: OKYO; NASDAQ: OKYO or the "Company"), an
ophthalmology-focused bio-pharmaceutical company which is
developing OK-101 to treat dry eye disease to address the
significant unmet need in this multi-billion-dollar market, today
announces the activation of the first clinical trial site in the
U.S. for its phase 2, multi-center, randomized, double-blinded,
placebo-controlled trial, evaluating the efficacy and safety of
OK-101 ophthalmic solution in subjects with dry eye disease. First
patient first visit is presently expected to occur within the next
two weeks.
"Our primary focus continues to be on advancing the clinical
development of OK-101 as a potential treatment option for dry eye
disease, a chronic ocular condition that affects roughly 700
million people worldwide," said Gary S. Jacob, Ph.D., CEO of OKYO
Pharma. "With the activation of our first clinical site we are now
very close to the opening of the OK-101 phase 2 trial and are
looking forward to initiating enrollment and completing the trial
before the end of the year."
About OK-101
OK-101 is a lipid conjugated chemerin peptide antagonist of the
ChemR23 G-protein coupled receptor which is typically found on
immune cells of the eye responsible for the inflammatory response.
OK-101 was developed using a membrane-anchored-peptide (MAP)
technology to produce a novel long-acting drug candidate for
treating dry eye disease. OK-101 has been shown to produce
anti-inflammatory and pain-reducing activities in mouse models of
dry eye disease and corneal neuropathic pain; and is designed to
combat washout through the inclusion of the lipid 'anchor'
contained in the candidate drug molecule to enhance the residence
time of OK-101 within the ocular environment.
About OKYO
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences
company admitted to listing on NASDAQ and on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the main market for listed securities of London Stock
Exchange plc. OKYO is focusing on the discovery and development of
novel molecules to treat inflammatory dry eye diseases and chronic
pain. For further information, please visit www.okyopharma.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
For further information, please visit the Company's website at
www.okyopharma.com
The person who arranged for the release of this announcement on
behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive
Officer of OKYO.
Enquiries:
Gary S. Jacob, Ph.D., Chief +44 (0)20 7495
OKYO Pharma Limited Executive Officer 2379
+44 (0)20 7495
Investor Relations Paul Spencer 2379
Optiva Securities
Limited +44 (0)20 3981
(Broker) Robert Emmet 4173
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEALLLAAPDEFA
(END) Dow Jones Newswires
April 25, 2023 02:00 ET (06:00 GMT)
Grafico Azioni Okyo Pharma (LSE:OKYO)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Okyo Pharma (LSE:OKYO)
Storico
Da Mag 2023 a Mag 2024